Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

Oncotarget

Volumn 7, Issue 28, 2016, Pages 43412-43418

  Jansen, Maurice P H M ^a   Martens, John W M ^a   Helmijr, Jean C A ^a   Beaufort, Corine M ^a   van Marion, Ronald ^a   Krol, Niels M G ^a,b   Monkhorst, Kim ^a   Trapman Jansen, Anita M A C ^a   Meijer van Gelder, Marion E ^a   Weerts, Marjolein J A ^a   Ramirez Ardila, Diana E ^a   Dubbink, Hendrikus Jan ^a   Foekens, John A ^a   Sleijfer, Stefan ^a   Berns, Els M J J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b Cancer Computational Biology Center   (Netherlands)

Author keywords

Breast cancer; Cell free DNA; Disease progression; Tamoxifen therapy; Targeted next generation sequencing

Indexed keywords

CELL DNA; CELL FREE DNA; SMAD4 PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; AKAP9 PROTEIN, HUMAN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CELL FREE NUCLEIC ACID; CREBBP PROTEIN, HUMAN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOSKELETON PROTEIN; DNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; SMAD4 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AKAP9 GENE; ARTICLE; BREAST METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CREBBP GENE; EXON; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; PIK3CA GENE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE VARIANT; SMAD4 GENE; BLOOD; BREAST; BREAST TUMOR; DISEASE EXACERBATION; DNA SEQUENCE; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY;

A KINASE ANCHOR PROTEINS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CELL-FREE NUCLEIC ACIDS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CREB-BINDING PROTEIN; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; DNA, NEOPLASM; EXONS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SMAD4 PROTEIN; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84978755588     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9727     Document Type: Article

References (26)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-1558.
2. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011; 17:667-677.
3. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:579-586.
4. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486:532-536.
5. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7:313ra182.
6. Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, et al. Sensitive Detection of Mono-and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res. 2016; 22:1130-1137.
7. Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016; 5.
8. Niu J, Andres G, Kramer K, Kundranda MN, Alvarez RH, Klimant E, Parikh AR, Tan B, Staren ED, Markman M. Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015; 8:3323-3328.
9. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, et al. ESR1 ligand-binding domain mutations in hormoneresistant breast cancer. Nat Genet. 2013; 45:1439-1445.
10. Frenel JS, Carreira S, Goodall J, Roda Perez D, Perez Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Smith A, Leux C, Garcia-Murillas I, et al. Serial Next Generation Sequencing of Circulating Cell Free DNA Evaluating Tumour Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res. 2015.
11. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw JA. Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer. Clin Chem. 2015; 61:974-982.
12. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer. 2007; 7:713-722.
13. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z, Cao X. Smad4 as a transcription corepressor for estrogen receptor alpha. J Biol Chem. 2003; 278:15192-15200.
14. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, SchiffR. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96:926-935.
15. Tram E, Ibrahim-Zada I, Briollais L, Knight JA, Andrulis IL, Ozcelik H. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR). Breast Cancer Res. 2011; 13:R77.
16. Kozak MM, von Eyben R, Pai J, Vossler SR, Limaye M, Jayachandran P, Anderson EM, Shaffer JL, Longacre T, Pai RK, Koong AC, Chang DT. Smad4 inactivation predicts for worse prognosis and response to fluorouracilbased treatment in colorectal cancer. J Clin Pathol. 2015; 68:341-345.
17. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, Hardisson D, Mendiola M, Gonzalez-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014; 23:6096-6111.
18. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer. 2002; 2:221-225.
19. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, Girard N, Tredaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014; 20:4613-4624.
20. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G, Callens C, Bieche I, Saliou A, Madic J, Rouleau E, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015; 9:783-790.
21. Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014; 25:1959-1965.
22. Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics. 2014; 15:244.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100:229-235.
24. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992; 52:1107-1113.
25. van Lier MG, Wagner A, van Leerdam ME, Biermann K, Kuipers EJ, Steyerberg EW, Dubbink HJ, Dinjens WN. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med. 2010; 14:181-197.
26. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013; 34:E2393-2402.